Breast CancerPhase 3NCT00087399
Gabapentin With or Without Antidepressants in Treating Hot Flashes in Women Who Have Had Breast Cancer or Have Concerns About Taking Hormone Therapy
A Phase 3 study testing gabapentin and antidepressant in people with Breast Cancer and Hot Flashes, run by Alliance for Clinical Trials in Oncology at 162 sites in United States.
Trial summary
RATIONALE: Gabapentin may be effective in relieving hot flashes in women who have had breast cancer or who have concerns about taking hormone therapy to treat hot flashes. It is not yet known whether gabapentin is more effective with or without antidepressants in treating hot flashes. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Breast Cancer, Hot Flashes
- What is being tested?
- gabapentin and antidepressant
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 118 participants
- Where
- 162 sitesUnited States
- Study dates
- Nov 2004to Apr 2007
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
DISEASE CHARACTERISTICS:
- History of breast cancer OR a concern about taking hormonal therapy due to a fear of developing breast cancer
- Experiencing bothersome hot flashes, defined as patient-reported occurrence ≥ 14 times per week AND sufficiently severe to prompt desire for additional therapeutic intervention despite current use of an antidepressant
- Currently (≥ 2 weeks) being treated with a stable dose of an antidepressant
- No monoamine oxidase inhibitors or tricyclics
- No current evidence of malignant disease
- Hormone receptor status:
- Not specified
PATIENT CHARACTERISTICS:
Age
- 18 and over
Sex
- Female
Performance status
- ECOG 0-1
Life expectancy
- At least 6 months
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective barrier contraception
PRIOR CONCURRENT THERAPY:
Chemotherapy
- More than 4 weeks since prior antineoplastic chemotherapy
- No concurrent antineoplastic chemotherapy
Endocrine therapy
- More than 4 weeks since prior androgens, estrogens, or progestational agents
- More than 2 weeks since prior dehydroepiandrosterone (DHEA) for treatment of hot flashes
- No concurrent androgens, estrogens, or progestational agents, including oral contraceptives
- No concurrent DHEA for treatment of hot flashes
- Concurrent tamoxifen, raloxifene, or aromatase inhibitor therapy allowed if on a stable dose for at least 4 weeks prior to study entry and during study treatment
Other
- No prior gabapentin
- More than 2 weeks since other prior treatment for hot flashes (e.g., clonidine or Bellergal-S®)
- Concurrent vitamin E or soy supplements allowed if on a stable dose for at least 1 month prior to study entry and during study treatment
- No other concurrent treatment for hot flashes (e.g., clonidine or Bellergal-S®)
- No other concurrent antidepressants
Trial locations and contacts
162 sites in 1 country.
162 sites in 1 country
United States162 sites
John and Dorothy Morgan Cancer Center at Lehigh Valley Hospital
Allentown, Pennsylvania, 18105
McFarland Clinic, P.C.
Ames, Iowa, 50010
Rose Ramer Cancer Clinic at Anderson Area Medical Center
Anderson, South Carolina, 29621
CCOP - Michigan Cancer Research Consortium
Ann Arbor, Michigan, 48100
St. Joseph Mercy Cancer Center at St. Joseph Mercy Hospital
Ann Arbor, Michigan, 48106-0995
MBCCOP-Medical College of Georgia Cancer Center
Augusta, Georgia, 30912
Rush-Copley Cancer Care Center
Aurora, Illinois, 60507
St. Francis Hospital and Health Centers
Beech Grove, Indiana, 46107
MeritCare Clinic - Bemidji
Bemidji, Minnesota, 56601
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
Deaconess Billings Clinic - Downtown
Billings, Montana, 59101
Northern Rockies Radiation Oncology Center
Billings, Montana, 59101
St. Vincent Healthcare
Billings, Montana, 59101
Deaconess Billings Clinic Cancer Center
Billings, Montana, 59107
Bismarck Cancer Center
Bismarck, North Dakota, 58501
Medcenter One Health System
Bismarck, North Dakota, 58501
Mid Dakota Clinic, P.C.
Bismarck, North Dakota, 58501
St. Alexius Medical Center
Bismarck, North Dakota, 58501
St. Joseph Medical Center
Bloomington, Illinois, 61701
Bozeman Deaconess Hospital
Bozeman, Montana, 59715
Brainerd Medical Center
Brainerd, Minnesota, 56401
St. Joseph's Medical Center
Brainerd, Minnesota, 56401
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
St. James Community Hospital
Butte, Montana, 59701
Graham Hospital
Canton, Illinois, 61520
Saint Anthony Regional Hospital
Carroll, Iowa, 51401
Memorial Hospital
Carthage, Illinois, 62321
St. Luke's Hospital
Cedar Rapids, Iowa, 52402
Cedar Rapids Oncology Associates
Cedar Rapids, Iowa, 52403
Mercy Cancer Center at Mercy Medical Center
Cedar Rapids, Iowa, 52403
Cancer Center of Kansas - Chanute
Chanute, Kansas, 66720
Mercy Hospital
Coon Rapids, Minnesota, 55433
Alegent Health Mercy Hospital
Council Bluffs, Iowa, 51503
Grandview Hospital
Dayton, Ohio, 45405
Good Samaritan Hospital
Dayton, Ohio, 45406
Samaritan North Cancer Care Center
Dayton, Ohio, 45415
Veterans Affairs Medical Center - Dayton
Dayton, Ohio, 45428
CCOP - Dayton
Dayton, Ohio, 45429
Mercy Capitol Hospital
Des Moines, Iowa, 50307
CCOP - Iowa Oncology Research Association
Des Moines, Iowa, 50309
John Stoddard Cancer Center at Iowa Methodist Medical Center
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates at John Stoddard Cancer Center
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates at Mercy Cancer Center
Des Moines, Iowa, 50314
Mercy Cancer Center at Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314
John Stoddard Cancer Center at Iowa Lutheran Hospital
Des Moines, Iowa, 50316
Cancer Center of Kansas - Dodge City
Dodge City, Kansas, 67801
Fairview Southdale Hospital
Edina, Minnesota, 55435
Cancer Center of Kansas, P.A. - El Dorado
El Dorado, Kansas, 67042
Green Bay Oncology, Limited - Escanaba
Escanaba, Michigan, 49431
Eureka Hospital
Eureka, Illinois, 61530
CCOP - MeritCare Hospital
Fargo, North Dakota, 58122
MeritCare Medical Group
Fargo, North Dakota, 58122
Genesys Hurley Cancer Institute
Flint, Michigan, 48532
Fremont Area Medical Center
Fremont, Nebraska, 68025
Mercy and Unity Cancer Center at Mercy and Unity Hospitals
Fridley, Minnesota, 55432
Galesburg Clinic
Galesburg, Illinois, 61401
Galesburg Cottage Hospital
Galesburg, Illinois, 61401
InterCommunity Cancer Center of Western Illinois
Galesburg, Illinois, 61401
Great Falls Clinic
Great Falls, Montana, 59405
Sletten Regional Cancer Institute
Great Falls, Montana, 59405
Green Bay Oncology, Limited at St. Vincent Hospital
Green Bay, Wisconsin, 54301-3526
St. Vincent Hospital
Green Bay, Wisconsin, 54301
Green Bay Oncology, Limited at St. Mary's Hospital
Green Bay, Wisconsin, 54303
St. Mary's Hospital Medical Center
Green Bay, Wisconsin, 54303
Mason District Hospital
Havana, Illinois, 62644
St. Peter's Hospital
Helena, Montana, 59601
Hopedale Medical Complex
Hopedale, Illinois, 61747
Hutchinson Area Health Care
Hutchinson, Minnesota, 55350
Green Bay Oncology, Limited - Iron Mountain
Iron Mountain, Michigan, 49801
Mayo Clinic - Jacksonville
Jacksonville, Florida, 32224-9980
Joliet Oncology Hematology Associates, Limited - West
Joliet, Illinois, 60435
Kalispell Regional Medical Center
Kalispell, Montana, 59901
Charles F. Kettering Memorial Hospital
Kettering, Ohio, 45429
Kewanee Hospital
Kewanee, Illinois, 61443
Cancer Center of Kansas - Kingman
Kingman, Kansas, 67068
Sparrow Regional Cancer Center
Lansing, Michigan, 48909
Southwest Medical Center
Liberal, Kansas, 67901
Bryan LGH Medical Center West
Lincoln, Nebraska, 68502
Cancer Resource Center - Lincoln
Lincoln, Nebraska, 68510
St. Elizabeth Regional Medical Center
Lincoln, Nebraska, 68510
Meeker County Memorial Hospital
Litchfield, Minnesota, 55355
McDonough District Hospital
Macomb, Illinois, 61455
St. John's Hospital
Maplewood, Minnesota, 55109
Mercy Cancer Center at Mercy Medical Center - North Iowa
Mason City, Iowa, 50401
Saint Anthony Memorial Health Centers
Michigan City, Indiana, 46360
Middletown Regional Hospital
Middletown, Ohio, 45044
Eastern Montana Cancer Center
Miles City, Montana, 59301
Virginia Piper Cancer Institute at Abbott-Northwestern Hospital
Minneapolis, Minnesota, 55407
Hennepin County Medical Center - Minneapolis
Minneapolis, Minnesota, 55415
Community Medical Center
Missoula, Montana, 59801
Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
Missoula, Montana, 59802
Alegent Health Community Memorial Hospital
Missouri Valley, Iowa, 51555
Trinity Medical Center - East
Moline, Illinois, 61265
Chippewa County - Montevideo Hospital
Montevideo, Minnesota, 56265
Cancer Center of Kansas - Newton
Newton, Kansas, 67114
BroMenn Regional Medical Center
Normal, Illinois, 61761
Community Cancer Center
Normal, Illinois, 61761
Green Bay Oncology, Limited - Oconto Falls
Oconto Falls, Wisconsin, 54154
CCOP - Missouri Valley Cancer Consortium
Omaha, Nebraska, 68106
Immanuel Medical Center
Omaha, Nebraska, 68122
Bergan Mercy Medical Center
Omaha, Nebraska, 68124
Cancer Center at Creighton University Medical Center
Omaha, Nebraska, 68131
Burgess Health Center
Onawa, Iowa, 51040
Community Hospital of Ottawa
Ottawa, Illinois, 61350
Oncology Hematology Associates of Central Illinois - Ottawa
Ottawa, Illinois, 61350
Cancer Center at Ottumwa Regional Health Center
Ottumwa, Iowa, 52501
Midlands Cancer Center at Midlands Community Hospital
Papillion, Nebraska, 68046
Cancer Center of Kansas, P.A. - Parsons
Parsons, Kansas, 67357
Cancer Treatment Center at Pekin Hospital
Pekin, Illinois, 61554
Methodist Medical Center of Illinois
Peoria, Illinois, 61603
Proctor Hospital
Peoria, Illinois, 61614
CCOP - Illinois Oncology Research Association
Peoria, Illinois, 61615
Oncology/Hematology Associates of Central Illinois, P.C.
Peoria, Illinois, 61615
OSF St. Francis Medical Center
Peoria, Illinois, 61637
Illinois Valley Community Hospital
Peru, Illinois, 61354
Pratt Cancer Center of Kansas
Pratt, Kansas, 67124
Perry Memorial Hospital
Princeton, Illinois, 61356
Hubert H. Humphrey Cancer Center at North Memorial Medical Center
Robbinsdale, Minnesota, 55422
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905
Rutherford Hospital
Rutherfordton, North Carolina, 28139
Seton Cancer Institute - Saginaw
Saginaw, Michigan, 48601
Adult and Pediatric Urology, P.L.L.P.
Saint Cloud, Minnesota, 56303
CentraCare Clinic - River Campus
Saint Cloud, Minnesota, 56303
St. Cloud Hospital
Saint Cloud, Minnesota, 56303
CCOP - Metro-Minnesota
Saint Louis Park, Minnesota, 55416
Park Nicollet Clinic
Saint Louis Park, Minnesota, 55416
Cancer Care Center at Regions Hospital
Saint Paul, Minnesota, 55101
St. Joseph's Hospital
Saint Paul, Minnesota, 55102
United Hospital
Saint Paul, Minnesota, 55102
Cancer Center of Kansas - Salina
Salina, Kansas, 67042
Guthrie Medical Center - Sayre
Sayre, Pennsylvania, 18840
CCOP - Mayo Clinic Scottsdale Oncology Program
Scottsdale, Arizona, 85259
Saint Francis Cancer Center
Shakopee, Minnesota, 55379
Welch Cancer Center
Sheridan, Wyoming, 82801
Siouxland Regional Cancer Center
Sioux City, Iowa, 51101-1733
Siouxland Hematology-Oncology Associates
Sioux City, Iowa, 51101
Mercy Medical Center - Sioux City
Sioux City, Iowa, 51104
St. Luke's Regional Medical Center
Sioux City, Iowa, 51104
Sioux Valley Hospital and University of South Dakota Medical Center
Sioux Falls, South Dakota, 57104
Avera McKennan Hospital and University Health Center
Sioux Falls, South Dakota, 57105
Medical X-Ray Center
Sioux Falls, South Dakota, 57105
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
Spartanburg, South Carolina, 29303
CCOP - Upstate Carolina
Spartanburg, South Carolina, 29304
St. Margaret's Hospital
Spring Valley, Illinois, 61362
Valley Cancer Center
Spring Valley, Illinois, 61362
Green Bay Oncology, Limited - Sturgeon Bay
Sturgeon Bay, Wisconsin, 54235
UVMC Cancer Care Center at Upper Valley Medical Center
Troy, Ohio, 45373
Carle Cancer Center at Carle Foundation Hospital
Urbana, Illinois, 61801
CCOP - Carle Cancer Center
Urbana, Illinois, 61801
Ridgeview Medical Center
Waconia, Minnesota, 55387
St. John Macomb Hospital
Warren, Michigan, 48903
Cancer Center of Kansas - Wellington
Wellington, Kansas, 67152
Medical Oncology and Hematology Associates - West Des Moines
West Des Moines, Iowa, 50266
Associates in Womens Health
Wichita, Kansas, 67203
Cancer Center of Kansas, P.A.
Wichita, Kansas, 67208
Cancer Center of Kansas, P.A. - Wichita
Wichita, Kansas, 67214
CCOP - Wichita
Wichita, Kansas, 67214
Via Christi Cancer Center at Via Christi Regional Medical Center
Wichita, Kansas, 67214
Cancer Center of Kansas - Winfield
Winfield, Kansas, 67156
Woodwinds Hospital
Woodbury, Minnesota, 55125
United States Air Force Medical Center Wright-Patterson
Wright-Patterson AFB, Ohio, 45433-5529
Ruth G. McMillan Cancer Center at Greene Memorial Hospital
Xenia, Ohio, 45385
About this study
Official title: A Phase III Randomized, Trial of Gabapentin Alone or in Conjunction With an Antidepressant in the Management of Hot Flashes in Women Who Have Inadequate Control With an Antidepressant Alone
RATIONALE: Gabapentin may be effective in relieving hot flashes in women who have had breast cancer or who have concerns about taking hormone therapy to treat hot flashes. It is not yet known whether gabapentin is more effective with or without antidepressants in treating hot flashes.
PURPOSE: This randomized phase III trial is studying gabapentin and antidepressants to see how well they work compared to antidepressants alone in treating hot flashes in women who have had breast cancer or who have concerns about taking hormones to treat hot flashes.
Read the detailed description
OBJECTIVES:
- Compare the efficacy of gabapentin with vs without an antidepressant, as measured by the frequency and intensity of hot flashes, in patients with a history of breast cancer or a concern about taking hormonal therapy due to a fear of developing breast cancer.
- Compare adverse events in patients treated with these regimens.
- Correlate a reduction in hot flash scores with improvement in quality of life and related outcomes in patients treated with these regimens.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to duration of hot flash symptoms (< 9 months vs ≥ 9 months), average frequency of hot flashes per day (2-3 vs 4-9 vs ≥ 10), and antidepressant currently being used (venlafaxine vs paroxetine vs other). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients continue to receive the same antidepressant (as before study entry) on weeks 1-5. During weeks 2-5, patients also receive oral gabapentin once daily on days 8-10, twice daily on days 11-13, and then three times daily on days 14-35 in the absence of unacceptable toxicity.
- Arm II: Patients receive gabapentin as in arm I. Patients are tapered off their antidepressant over 7-10 days and remain on gabapentin alone (per arm I schedule).
Patients in both arms complete a hot flash diary at baseline and then daily during study treatment.
Quality of life is assessed at baseline and then weekly during study treatment.
PROJECTED ACCRUAL: A total of 110 patients (55 per treatment arm) will be accrued for this study within 2 years.
- Conditions
- Breast Cancer, Hot Flashes
- Being tested
- gabapentin, antidepressant
- Keywords
- breast cancer, hot flashes
- Medical subject headings
- Breast Neoplasms, Hot Flashes
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
gabapentinDrug
antidepressantDrug
| Study group | Role | What they receive |
|---|---|---|
| gabapentin + antidepressant | Experimental | Patients continue to receive the same antidepressant (as before study entry) on weeks 1-5. During weeks 2-5, patients also receive oral gabapentin once daily on days 8-10, twice daily on days 11-13, and then three times daily on days 14-35 in the absence of unacceptable toxicity.
Patients complete a hot flash diary at baseline and then daily during study treatment. Receives: Drug: gabapentin; Drug: antidepressant |
| gabapentin | Experimental | Patients receive gabapentin once daily on days 8-10, twice daily on days 11-13, and then three times daily on days 14-35 in the absence of unacceptable toxicity. Patients are tapered off their antidepressant over 7-10 days and remain on gabapentin alone.
Patients complete a hot flash diary at baseline and then daily during study treatment. Receives: Drug: gabapentin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Hot flash reduction by diary record at 4 weeks
Measured: at 4 weeks
Secondary outcomes (1)
Toxicity by questionnaires at 4 weeks
Measured: at 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jul 2004 (estimated)
- Study startNov 2004
- Primary completionApr 2007
- Study completionApr 2007
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- More trials run by Alliance for Clinical Trials in OncologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 118 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Charles L. Loprinzi, MD, Study chair, Mayo Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00087399
- Sponsor's protocol ID
- NCCTG-N03C5
- Other IDs
- NCI-2012-02616, CDR0000374993
- Status last verified
- Jul 2016
- First submitted
- 8 Jul 2004
- Last updated
- 14 Jul 2016
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Loprinzi CL, Kugler JW, Barton DL, Dueck AC, Tschetter LK, Nelimark RA, Balcueva EP, Burger KN, Novotny PJ, Carlson MD, Duane SF, Corso SW, Johnson DB, Jaslowski AJ. Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5. J Clin Oncol. 2007 Jan 20;25(3):308-12. doi: 10.1200/JCO.2006.07.5390. Epub 2006 Dec 4.
PubMed 17146104Loprinzi CL, Kugler JW, Barton DL, et al.: Phase III randomized trial to evaluate the use of gabapentin alone vs with continuing an antidepressant in women failing an antidepressant for the treatment of hot flashes: North Central Cancer Treatment Group study N03C5. [Abstract] J Clin Oncol 24 (Suppl 18): A-526, 9s, 2006.
Study at a glance
From the registry record, last updated by the sponsor on 14 Jul 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase III Randomized, Trial of Gabapentin Alone or in Conjunction With an Antidepressant in the Management of Hot Flashes in Women Who Have Inadequate Control With an Antidepressant Alone
- ClinicalTrials.gov ID
- NCT00087399
- Acronym / sponsor ID
- NCCTG-N03C5
- Conditions
- Breast Cancer, Hot Flashes
- Keywords
- breast cancer, hot flashes
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 118 participants (actual)
- Lead sponsor
- Alliance for Clinical Trials in OncologyUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- Nov 2004
- Primary completion
- Apr 2007 (actual)
- Study completion
- Apr 2007 (actual)
- First posted
- 12 Jul 2004 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Gabapentin may be effective in relieving hot flashes in women who have had breast cancer or who have concerns about taking hormone therapy to treat hot flashes. It is not yet known whether gabapentin is more effective with or without antidepressants in treating hot flashes.
PURPOSE: This randomized phase III trial is studying gabapentin and antidepressants to see how well they work compared to antidepressants alone in treating hot flashes in women who have had breast cancer or who have concerns about taking hormones to treat hot flashes.
Detailed description
OBJECTIVES:
- Compare the efficacy of gabapentin with vs without an antidepressant, as measured by the frequency and intensity of hot flashes, in patients with a history of breast cancer or a concern about taking hormonal therapy due to a fear of developing breast cancer.
- Compare adverse events in patients treated with these regimens.
- Correlate a reduction in hot flash scores with improvement in quality of life and related outcomes in patients treated with these regimens.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to duration of hot flash symptoms (< 9 months vs ≥ 9 months), average frequency of hot flashes per day (2-3 vs 4-9 vs ≥ 10), and antidepressant currently being used (venlafaxine vs paroxetine vs other). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients continue to receive the same antidepressant (as before study entry) on weeks 1-5. During weeks 2-5, patients also receive oral gabapentin once daily on days 8-10, twice daily on days 11-13, and then three times daily on days 14-35 in the absence of unacceptable toxicity.
- Arm II: Patients receive gabapentin as in arm I. Patients are tapered off their antidepressant over 7-10 days and remain on gabapentin alone (per arm I schedule).
Patients in both arms complete a hot flash diary at baseline and then daily during study treatment.
Quality of life is assessed at baseline and then weekly during study treatment.
PROJECTED ACCRUAL: A total of 110 patients (55 per treatment arm) will be accrued for this study within 2 years.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| gabapentin + antidepressant | Experimental | Drug: gabapentin, Drug: antidepressantPatients continue to receive the same antidepressant (as before study entry) on weeks 1-5. During weeks 2-5, patients also receive oral gabapentin once daily on days 8-10, twice daily on days 11-13, and then three times daily on days 14-35 in the absence of unacceptable toxicity. Patients complete a hot flash diary at baseline and then daily during study treatment. |
| gabapentin | Experimental | Drug: gabapentinPatients receive gabapentin once daily on days 8-10, twice daily on days 11-13, and then three times daily on days 14-35 in the absence of unacceptable toxicity. Patients are tapered off their antidepressant over 7-10 days and remain on gabapentin alone. Patients complete a hot flash diary at baseline and then daily during study treatment. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| gabapentin | Drug | gabapentin, gabapentin + antidepressant |
| antidepressant | Drug | gabapentin + antidepressant |
Primary outcome
Hot flash reduction by diary record at 4 weeks
Time frame: at 4 weeks
1 secondary outcome
Toxicity by questionnaires at 4 weeks
Time frame: at 4 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jul 2016.
- Results publication: PubMed 17146104Loprinzi CL, Kugler JW, Barton DL, Dueck AC, Tschetter LK, Nelimark RA, Balcueva EP, Burger KN, Novotny PJ, Carlson MD, Duane SF, Corso SW, Johnson DB, Jaslowski AJ. Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5. J Clin Oncol. 2007 Jan 20;25(3):308-12. doi: 10.1200/JCO.2006.07.5390. Epub 2006 Dec 4.
- Results publicationLoprinzi CL, Kugler JW, Barton DL, et al.: Phase III randomized trial to evaluate the use of gabapentin alone vs with continuing an antidepressant in women failing an antidepressant for the treatment of hot flashes: North Central Cancer Treatment Group study N03C5. [Abstract] J Clin Oncol 24 (Suppl 18): A-526, 9s, 2006.
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Charles L. Loprinzi, MD study chair
Mayo Clinic
162 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing gabapentin and antidepressant in people with Breast Cancer and Hot Flashes, run by Alliance for Clinical Trials in Oncology at 162 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Jul 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 162 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Hot flash reduction by diary record at 4 weeks (time frame: at 4 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00087399, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jul 2016.